摘要
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has been spreading globally since its initial outbreak in 2019.Substantial evidence has revealed that children who are receiving antitumor therapy or hematopoietic stem cell transplantation(HSCT)present higher rates of severe illness and mortality[1].It is important to identify infected children with hematology and oncology diseases who have the tendency to develop worse outcomes of coronal virus disease 2019(COVID-19)during the early stage of COVID-19.Recent studies have demonstrated that vaccination against SARS-CoV-2 in adults can reduce the likelihood of infection and reduce the severity and mortality of COVID-19 when SARS-CoV-2 breakthrough infection occurs[2,3,4].However,the effectiveness of SARS-CoV-2 vaccination in children with hematology and oncology diseases is poorly defined due to the lack of relevant data,which might lead to vaccine hesitancy[5,6].
